Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (308638) 308638
Book / eBook (455) 455
Book Chapter (242) 242
Magazine Article (168) 168
Dissertation (139) 139
Conference Proceeding (45) 45
Government Document (40) 40
Publication (37) 37
Web Resource (16) 16
Streaming Video (10) 10
Newsletter (4) 4
Newspaper Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (267316) 267316
science & technology (259090) 259090
life sciences & biomedicine (239826) 239826
oncology (129818) 129818
animals (113664) 113664
female (111006) 111006
cell line, tumor (82558) 82558
cancer (80480) 80480
male (78991) 78991
biological and medical sciences (69105) 69105
tumors (68507) 68507
mice (64575) 64575
medical sciences (61944) 61944
middle aged (49925) 49925
apoptosis (45449) 45449
aged (40844) 40844
research (38012) 38012
adult (37114) 37114
antineoplastic agents - pharmacology (36065) 36065
apoptosis - drug effects (35996) 35996
chemotherapy (35692) 35692
cell biology (35630) 35630
biochemistry & molecular biology (33024) 33024
care and treatment (32583) 32583
proteins (31974) 31974
breast cancer (31207) 31207
gene expression (30784) 30784
cell proliferation - drug effects (29096) 29096
health aspects (28827) 28827
antineoplastic agents (28206) 28206
analysis (28107) 28107
metastasis (28030) 28030
tumor cells, cultured (27083) 27083
pharmacology & pharmacy (26630) 26630
antineoplastic agents - therapeutic use (26502) 26502
pharmacology. drug treatments (26196) 26196
signal transduction (24567) 24567
genetic aspects (24368) 24368
prognosis (23463) 23463
neoplasms - drug therapy (23000) 23000
gene expression regulation, neoplastic (22210) 22210
cancer therapies (21336) 21336
research article (21065) 21065
mice, nude (20976) 20976
cell proliferation (20220) 20220
mutation (20043) 20043
kinases (19712) 19712
signal transduction - drug effects (19689) 19689
treatment outcome (19138) 19138
breast neoplasms - pathology (18922) 18922
science & technology - other topics (18849) 18849
development and progression (18736) 18736
medicine & public health (18645) 18645
medicine (17653) 17653
medicine, research & experimental (17209) 17209
research & experimental medicine (17191) 17191
dose-response relationship, drug (17038) 17038
cell cycle (16949) 16949
gene expression regulation, neoplastic - drug effects (16777) 16777
immunohistochemistry (16655) 16655
xenograft model antitumor assays (16629) 16629
cell survival - drug effects (16455) 16455
multidisciplinary sciences (16236) 16236
breast neoplasms - drug therapy (15526) 15526
neoplasms. tumors. oncology. including cancer and carcinogens (15251) 15251
aged, 80 and over (15226) 15226
neoplasms - pathology (14870) 14870
rats (14836) 14836
drug resistance, neoplasm (14568) 14568
neoplasms - metabolism (14559) 14559
breast neoplasms - metabolism (14553) 14553
physiological aspects (14476) 14476
blotting, western (14342) 14342
risk factors (14252) 14252
hematology (14104) 14104
abridged index medicus (14048) 14048
cancer research (14007) 14007
studies (13889) 13889
lung cancer (13874) 13874
medical prognosis (13577) 13577
phosphorylation (13505) 13505
colorectal cancer (13366) 13366
mice, inbred balb c (13313) 13313
drug therapy (13297) 13297
immunotherapy (13022) 13022
cell growth (12553) 12553
antineoplastic combined chemotherapy protocols - therapeutic use (12547) 12547
medical research (12067) 12067
prostate cancer (12050) 12050
transfection (11989) 11989
neoplasms (11976) 11976
biology (11975) 11975
flow cytometry (11716) 11716
lung neoplasms - drug therapy (11650) 11650
genes (11631) 11631
science (11623) 11623
neoplasms - genetics (11594) 11594
lung neoplasms - pathology (11593) 11593
patients (11571) 11571
drug resistance (11532) 11532
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (111) 111
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (33) 33
Collection Dvlpm't (Acquisitions) - Vendor file (31) 31
Online Resources - Online (21) 21
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
UofT at Mississauga - Stacks (9) 9
UofT at Scarborough - Stacks (4) 4
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
St. Michael's Hospital - Stacks (3) 3
Trinity College (John W Graham) - Stacks (3) 3
Victoria University E.J. Pratt - Oversize (3) 3
Earth Sciences (Noranda) - Circulation Desk (2) 2
Earth Sciences (Noranda) - Oversize (2) 2
Earth Sciences (Noranda) - Stacks (2) 2
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reserve desk (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Reference (2) 2
UofT at Mississauga - Circulation Desk (2) 2
Victoria University E.J. Pratt - Circulation Desk (2) 2
Women's College Hospital - Stacks (2) 2
Credit Valley Hospital - Reserve desk (1) 1
Gerstein Science - Processing (1) 1
Lakeridge Health Sciences - Stacks (1) 1
Physics - Course Reserves (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's College (John M. Kelly) - Circulation Desk (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (307189) 307189
Chinese (2563) 2563
Japanese (1354) 1354
German (646) 646
Russian (495) 495
French (488) 488
Portuguese (184) 184
Spanish (137) 137
Polish (119) 119
Italian (93) 93
Hungarian (68) 68
Norwegian (62) 62
Dutch (53) 53
Ukrainian (22) 22
Czech (21) 21
Croatian (18) 18
Korean (18) 18
Turkish (15) 15
Swedish (14) 14
Danish (10) 10
Romanian (7) 7
Serbian (7) 7
Bulgarian (5) 5
Hebrew (5) 5
Finnish (3) 3
Persian (3) 3
Slovak (2) 2
Slovenian (2) 2
Afar (1) 1
Afrikaans (1) 1
Amharic (1) 1
Arabic (1) 1
Kurdish (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
by Zhang, Pingzhao and Wang, Dejie and Zhao, Yu and Ren, Shancheng and Gao, Kun and Ye, Zhenqing and Wang, Shangqian and Pan, Chun-Wu and Zhu, Yasheng and Yan, Yuqian and Yang, Yinhui and Wu, Di and He, Yundong and Zhang, Jun and Lu, Daru and Liu, Xiuping and Yu, Long and Zhao, Shimin and Li, Yao and Lin, Dong and Wang, Yuzhuo and Wang, Liguo and Chen, Yu and Sun, Yinghao and Wang, Chenji and Huang, Haojie
Nature medicine, ISSN 1078-8956, 09/2017, Volume 23, Issue 9, pp. 1055 - 1062
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Prostatic Neoplasms - metabolism | Immunoprecipitation | TOR Serine-Threonine Kinases - metabolism | Humans | Drug Resistance, Neoplasm | Male | Gene Expression Profiling | Molecular Targeted Therapy | Mechanistic Target of Rapamycin Complex 1 | Transcription Factors - drug effects | Multiprotein Complexes - metabolism | Prostatic Neoplasms - genetics | Proteasome Endopeptidase Complex - drug effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Nuclear Proteins - drug effects | Nuclear Proteins - genetics | Proto-Oncogene Proteins c-akt - metabolism | TOR Serine-Threonine Kinases - drug effects | Multiprotein Complexes - drug effects | Prostatic Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - metabolism | Repressor Proteins - metabolism | RNA-Binding Proteins - antagonists & inhibitors | Triazoles - therapeutic use | Cell Survival | Repressor Proteins - genetics | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Azepines - therapeutic use | RNA-Binding Proteins - drug effects | Azepines - pharmacology | Transcription Factors - metabolism | Triazoles - pharmacology | Nuclear Proteins - antagonists & inhibitors | Protein-Serine-Threonine Kinases - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | RNA-Binding Proteins - metabolism | rac1 GTP-Binding Protein - metabolism | Proto-Oncogene Proteins c-akt - drug effects | rac1 GTP-Binding Protein - genetics | Gene mutations | Physiological aspects | Genetic aspects | Research | Drug resistance | Drug therapy | Prostate cancer | Ubiquitin | Inhibitor drugs | Stabilization | AKT protein | Biosynthesis | Degradation | Proteins | Ubiquitination | Transcription activation | Ubiquitin-protein ligase | Binding | Rac1 protein | Guanosine triphosphatases | Tumor cell lines | Gene expression | Cholesterol | Mutants | Inhibitors | Proteasomes | Biomarkers | Bet protein | Prostate | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
by Sun, Chong and Wang, Liqin and Huang, Sidong and Heynen, Guus J J E and Prahallad, Anirudh and Robert, Caroline and Haanen, John and Blank, Christian and Wesseling, Jelle and Willems, Stefan M and Zecchin, Davide and Hobor, Sebastijan and Bajpe, Prashanth K and Lieftink, Cor and Mateus, Christina and Vagner, Stephan and Grernrum, Wipawadee and Hofland, Ingrid and Schlicker, Aneas and Wessels, Lodewyk F A and Beijersbergen, Roderick L and Bardelli, Alberto and Di Nicolantonio, Federica and Eggermont, Alexander M M and Bernards, Rene
Nature (London), ISSN 0028-0836, 04/2014, Volume 508, Issue 7494, pp. 118 - 22
Antineoplastic Agents/administration & dosage | Transforming Growth Factor beta/metabolism | Humans | Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | Indoles/administration & dosage | Flow Cytometry | Receptor, Platelet-Derived Growth Factor beta/biosynthesis | Proto-Oncogene Proteins B-raf/antagonists & inhibitors | ErbB Receptors/biosynthesis | Melanoma/drug therapy | Female | Cell Proliferation/drug effects | Sulfonamides/administration & dosage | Gene Library | Cellular Senescence/drug effects | Receptor Protein-Tyrosine Kinases/biosynthesis | Drug Resistance, Neoplasm/drug effects | Gene Expression Regulation, Neoplastic/drug effects | SOXE Transcription Factors/deficiency | Signal Transduction/drug effects | Protein Kinase Inhibitors/administration & dosage | Vemurafenib | Animals | Mice | RNA, Small Interfering | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Receptor, Epidermal Growth Factor - genetics | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Melanoma - genetics | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | Patients | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
by Legrier, Marie-Emmanuelle and Bièche, Ivan and Gaston, Julie and Beurdeley, Arnaud and Yvonnet, Vanessa and Déas, Olivier and Thuleau, Aurélie and Château-Joubert, Sophie and Servely, Jean-Luc and Vacher, Sophie and Lassalle, Myriam and Depil, Stéphane and Tucker, Gordon C and Fontaine, Jean-Jacques and Poupon, Marie-France and Roman-Roman, Sergio and Judde, Jean-Gabriel and Decaudin, Didier and Cairo, Stefano and Marangoni, Elisabetta
British journal of cancer, ISSN 0007-0920, 01/2016, Volume 114, Issue 2, pp. 177 - 187
Life Sciences & Biomedicine | Oncology | Science & Technology | Caspase 7 - metabolism | Immunohistochemistry | Receptors, Estrogen - metabolism | Cytoskeletal Proteins - genetics | Humans | Intracellular Signaling Peptides and Proteins - drug effects | Caspase 3 - metabolism | Gene Expression Profiling | Intracellular Signaling Peptides and Proteins - metabolism | Interferon-gamma - metabolism | Carrier Proteins - drug effects | Mitochondrial Proteins - drug effects | STAT1 Transcription Factor - metabolism | Mitochondrial Proteins - metabolism | Caspase 3 - genetics | Interferon-beta - genetics | Cytokines - genetics | Intracellular Signaling Peptides and Proteins - genetics | Real-Time Polymerase Chain Reaction | Ubiquitins - metabolism | Caspase 7 - drug effects | Antigens - drug effects | Caspase 7 - genetics | Membrane Proteins - genetics | Myxovirus Resistance Proteins - drug effects | Capecitabine - pharmacology | STAT1 Transcription Factor - genetics | Breast Neoplasms - drug therapy | Blotting, Western | Breast Neoplasms - genetics | Interferon-beta - metabolism | Signal Transduction - drug effects | Mice, Nude | Membrane Proteins - drug effects | Mice | Myxovirus Resistance Proteins - genetics | Ubiquitins - drug effects | Antigens - genetics | Neoplasm Transplantation | Phosphorylation | Ubiquitins - genetics | Gene Expression Regulation, Neoplastic | Interferon-gamma - drug effects | STAT1 Transcription Factor - drug effects | Mitochondrial Proteins - genetics | Interferon-beta - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | In Situ Hybridization | Caspase 3 - drug effects | Cytoskeletal Proteins - metabolism | Female | Cytoskeletal Proteins - drug effects | Membrane Proteins - metabolism | Interferon-gamma - genetics | Cytokines - metabolism | Antigens - metabolism | Cisplatin - pharmacology | Xenograft Model Antitumor Assays | Carrier Proteins - genetics | Animals | Carrier Proteins - metabolism | Cytokines - drug effects | Myxovirus Resistance Proteins - metabolism | Index Medicus | Life Sciences | Computer Science | IFN | Translational Therapeutics | STAT1 | chemotherapy | predictive signature | ER-negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Activation of ATM Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells
by Sahu, R.P and Batra, S and Srivastava, S.K
British journal of cancer, ISSN 0007-0920, 05/2009, Volume 100, Issue 9, pp. 1425 - 1433
Curcumin | Chk1 | G2/M arrest | DNA damage | Pancreatic cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Cell Cycle Proteins - drug effects | Protein Kinases - metabolism | Gene Expression Regulation, Enzymologic - drug effects | Protein Kinases - genetics | Gene Silencing - drug effects | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Collagen Type XI - metabolism | DNA-Binding Proteins - metabolism | Pancreatic Neoplasms - drug therapy | Transfection | Tumor Suppressor Proteins - genetics | Caspase 3 - drug effects | Cell Cycle Proteins - genetics | Gene Expression Regulation, Neoplastic - drug effects | Protein-Serine-Threonine Kinases - metabolism | DNA Damage - drug effects | Protein Kinases - drug effects | Tumor Suppressor Proteins - metabolism | Collagen Type XI - drug effects | Pancreatic Neoplasms - pathology | Cell Cycle Proteins - metabolism | Curcumin - pharmacology | DNA-Binding Proteins - drug effects | Pancreatic Neoplasms - enzymology | Protein-Serine-Threonine Kinases - genetics | Ataxia Telangiectasia Mutated Proteins | DNA-Binding Proteins - genetics | Cell Division - drug effects | Protein-Serine-Threonine Kinases - drug effects | Cell Line, Tumor | Checkpoint Kinase 1 | Tumor Suppressor Proteins - drug effects | Cell Cycle - drug effects | Index Medicus | Translational Therapeutics | pancreatic cancer | M arrest | curcumin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
by Shu, Shaokun and Lin, Charles Y and He, Housheng Hansen and Witwicki, Robert M and Tabassum, Doris P and Roberts, Justin M and Janiszewska, Michalina and Huh, Sung Jin and Liang, Yi and Ryan, Jeremy and Doherty, Ernest and Mohammed, Hisham and Guo, Hao and Stover, Daniel G and Ekram, Muhammad B and Peluffo, Guillermo and Brown, Jonathan and D'Santos, Clive and Krop, Ian E and Dillon, Deborah and McKeown, Michael and Ott, Christopher and Qi, Jun and Ni, Min and Rao, Prakash K and Duarte, Melissa and Wu, Shwu-Yuan and Chiang, Cheng-Ming and Anders, Lars and Young, Richard A and Winer, Eric P and Letai, Antony and Barry, William T and Carroll, Jason S and Long, Henry W and Brown, Myles and Liu, X. Shirley and Meyer, Clifford A and Bradner, James E and Polyak, Kornelia
Nature (London), ISSN 0028-0836, 01/2016, Volume 529, Issue 7586, pp. 413 - 417
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Antimitotic agents | Enzyme inhibitors | Patient outcomes | Breast cancer | Dosage and administration | Drug therapy | Antineoplastic agents | Studies | Inhibitor drugs | Drug resistance | Gene expression | Drug dosages | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
by Peters, Solange and Camidge, D. Ross and Shaw, Alice T and Gadgeel, Shirish and Ahn, Jin S and Kim, Dong-Wan and Ou, Sai-Hong I and Pérol, Maurice and Dziadziuszko, Rafal and Rosell, Rafael and Zeaiter, Ali and Mitry, Emmanuel and Golding, Sophie and Balas, Bogdana and Noe, Johannes and Morcos, Peter N and Mok, Tony and ALEX Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
by Hatzivassiliou, Georgia and Song, Kyung and Yen, Ivana and Brandhuber, Barbara J and Anderson, Daniel J and Alvarado, Ryan and Ludlam, Mary J. C and Stokoe, David and Gloor, Susan L and Vigers, Guy and Morales, Tony and Aliagas, Ignacio and Liu, Bonnie and Sideris, Steve and Hoeflich, Klaus P and Jaiswal, Bijay S and Seshagiri, Somasekar and Koeppen, Hartmut and Belvin, Marcia and Friedman, Lori S and Malek, Shiva
Nature (London), ISSN 0028-0836, 03/2010, Volume 464, Issue 7287, pp. 431 - 435
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | General aspects | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Animal tumors. Experimental tumors | Experimental tumors, general aspects | Antineoplastic agents | Tumors | Neoplasms - metabolism | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Diphenylamine - pharmacology | raf Kinases - antagonists & inhibitors | Humans | Protein Multimerization | ras Proteins - metabolism | Protein Transport - drug effects | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | Diphenylamine - analogs & derivatives | Mitogen-Activated Protein Kinase Kinases - metabolism | Adenosine Triphosphate - metabolism | Indoles - pharmacology | Benzamides - pharmacology | Cell Membrane - metabolism | raf Kinases - genetics | Cell Membrane - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Pyrazoles - pharmacology | Protein Structure, Tertiary | Proto-Oncogene Proteins - metabolism | Cell Line | Indenes - pharmacology | raf Kinases - chemistry | Proto-Oncogene Proteins c-raf - genetics | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-raf - metabolism | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Proto-Oncogene Proteins c-raf - deficiency | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Neoplasms - pathology | Ras genes | Growth | Physiological aspects | Cellular signal transduction | Genetic aspects | Research | Mitogen-activated protein kinases | Competition | Clinical trials | Enzymes | Kinases | Index Medicus | Proteins | Cellular | Inhibitors | Pathways | Tumours | Signalling | Dimerization
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights